Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor decision stopped in June 2017
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether term SGA infants who are fed a nutrient-enriched pre-term formula will have a higher cognitive score, a more appropriate length-for-age Z-score (leading to a lower prevalence of Stunting) but higher blood pressure at 2 years of age compared to term SGA infants who are fed on a regular starter formula.
This is multi-sites, interventional, double-blinded, randomized, 2-arm parallel-group clinical trial. Two HM fed groups will be included as comparator group.
The primary objectives are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Randomized Standard Formula-fed | Experimental | Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months). |
|
| Randomized Nutrient-enriched formula-fed | Experimental | Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months). |
|
| Non-randomized HM-fed | No Intervention | Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice. | |
| Non-Randomized HM-fed | No Intervention | Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard Formula | Other | Standard Formula |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of neurodevelopment | Assessed using Bayley Scales of Infant and Toddler DevelopmentĀ® - Third Edition - (To compare with the standard Bayley scores). | at the baseline (2 years of age) |
| Evaluation of length-for-age Z-score | Using the WHO growth chart | Evaluated once at 2 years of age |
| Systolic Blood pressure | Systolic and diastolic blood pressure measurement from 1 to 6 months of age | at baseline (2 years of age) |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of insulin sensitivity | HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations. | at Baseline ( 2 years of age). |
| Evaluation of insulin sensitivity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nutrient-enriched Formula |
| Other |
Nutrient-enriched Formula |
|
HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations.
| at last visit ( 5 years of age). |
| Neurodevelopment | Assessed using Wechsler Preschool and Primary Scale of Intelligence⢠- Fourth Edition (WPPSI-IV) - (to compare the scores against the standard scores). | At last visit ( 5 years of age) |
| Safety (Adverse Event reporting) | Assessed by Type, incidence, severity, seriousness and relationship to study formulas of AEs (including Infection) among the study subjects. | From 1 to 6 months of age & 6 months to 5 years of age. |
| Growth (Length) | Evaluation of length-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting). | At 2 years of age |
| Growth (Weight) | Evaluation of weight-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting). | At 2 years of age |
| Growth (Head circumference) | Evaluation of head circumference-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting). | At 2 years of age |
| Growth (Z-Scores) | Evaluation of weight-for-length Z-scores in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting). | At 2 years of age |
| Evaluation of serum markers of bone metabolism | Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase). | At visit 1 (<44 days) |
| Evaluation of serum markers of bone metabolism | Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase). | At visit 4 (6 months) |
| Evaluation of urinary markers of bone metabolism | Assessed by Incidence of urine biochemistries (calcium, phosphorous). | At visit 1 (<44 days) |
| Evaluation of urinary markers of bone metabolism | Assessed by Incidence of urine biochemistries (calcium, phosphorous). | At visit 4 (6 months) |
| Body fat mass (%) | Assessed by Deterium dilution | evaluated until 5 years of age. |